Hematology

Latest News

One of the key ways to manage thromboembolic event risk in PV is by controlling hematocrit, often by prescribing hydroxyurea. If patients develop resistance to the therapy, however, they face a higher risk of mortality. | Image credit: keetazalay - stock.adobe.com
Machine Learning Model Identifies Hydroxyurea Resistance Markers in PV

May 6th 2025

Machine learning identifies key biomarkers predicting hydroxyurea resistance in polycythemia vera, enhancing early treatment strategies and patient outcomes.

While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com
Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

May 1st 2025

Researchers analyzed matched cohorts of patients who received either decitabine-cedazuridine with venetoclax or decitabine-cedazuridine alone to determine how the addition of venetoclax impacts outcomes in higher-risk MDS and CMML. |Image credit: syahrir - stock.adobe.com
Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

April 25th 2025

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

April 25th 2025

The investigators found that people with MPNs and at least one CVRF had an increased risk of both death and arterial or venous thrombosis. | Image credit: Dr_Microbe - stock.adobe.com
Cardiovascular Risk Factors Impact Outcomes in MPNs

April 21st 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Tablet with blue screen and multiple myeloma written in white with a stethoscope on top | Image credit: ibreakstock-stock.adobe.com
September 14th 2024

CAR T Reduces All-Cause Mortality Greater Than a Bispecific Antibody in MM

Laura Joszt, MA
Using real-world data, researchers compared 2 chimeric antigen receptor (CAR) T-cell therapies with a bispecific antibody, teclistamab, in multiple myeloma (MM).
Celiac disease and the body | Image Credit: reineg-stock.adobe.com
September 13th 2024

Celiac Disease Associated With Varying Risks for Cancers

Karen Jacobson-Sive
Celiac disease presents a higher risk for developing malignant neoplasms, including small intestine, lymphoma, and skin cancers, but presents a lower risk for respiratory malignancies.
Patients with SCD have reportedly felt stigmatized due to their race, pain, and more | image credit: Andrey Popov - stock.adobe.com
September 11th 2024

Study: Patients With SCD Report Discrimination Based on Race, Pain, and Other Factors

Jared Kaltwasser
A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood.
Recombinant Hirudin shows promise in the treament of DLBCL | image credit: David A Litman - stock.adobe.com
September 5th 2024

Recombinant Hirudin May Help Treat Diffuse Large B-Cell Lymphoma 

Karen Jacobson-Sive
Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL).
red blood cells model CLL | image credit: digitalpochi - stock.adobe.com
September 4th 2024

B-Cell Activating Factor Levels May Predict Reduced Risk of CLL, Study Finds

Kimberly Rath, PharmD
A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential biomarkers for assessing CLL risk.
Telomeres act as protective caps on the ends of chromosomes | image credit: Anastasiia - stock.adobe.com
September 3rd 2024

RIOK2 Regulates Telomerase Subunits to Prevent Telomere Shortening

Gwen Mergian
New research linking telomere shortening to myelodysplastic syndromes (MDS) offers substantial therapeutic implications for affected patients and MDS research.
Despite treatment, some patients with PNH still experience anemia | image credit: ImageFlow - stock.adobe.com
August 28th 2024

Pegcetacoplan May Reduce Fatigue in PNH Accompanied by Anemia

Kyle Munz
Findings from a post hoc analysis of 3 clinical trials support the switching to or initiation of pegcetacoplan to manage fatigue for patients with paroxysmal nocturnal hemoglobinuria (PNH) that is accompanied by mild to moderate anemia.
Immunology word cloud | image credit: ibreakstock - stock.adobe.com
August 27th 2024

Researchers Identify Potential IO Targets in AML Through Surfaceome Analysis

AJMC Contributor
By analyzing the surface proteome of a wide-ranging sample of acute myeloid leukemia (AML) specimens, researchers identified potential antigens and primitive cell markers representative of AML supgroups.
Cancerous cells | image credit: Dr_Microbe - stock.adobe.com
August 26th 2024

Multiplex Spatial Analysis Highlights Mechanisms of Refractory cHL

Jared Kaltwasser
Improvements in multiplex immunofluorescence and spatial analysis have enabled a better understanding of the ways classical Hodgkin lymphoma evades the immune system.
Skin cancer is a dangerous morbidity risk in patients with CLL | image credit: Ocskay Mark - stock.adobe.com
August 26th 2024

Study Implicates AXL in Skin Cancer Development in CLL

Jared Kaltwasser
The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy.
Leland Metheny, MD, University Hospitals Seidman Cancer Center
August 24th 2024

New CAR T Trial in MM Aims for Triple Receptor Targeting

Maggie L. Shaw
Leland Metheny, MD, is lead investigator for the Phase 1 BAFF CAR T clinical trial, which is evaluating the safety and effectiveness of a novel approach to chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) that targets 3 receptors on cancer cells and uses electroporation vs the typical lentiviral vector delivery.
stem cells | Image Credit: jarun011-stock.adobe.com
August 20th 2024

Second ASCT Extends Survival in Relapsed Multiple Myeloma

Maggie L. Shaw
To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.
CLL cells | image credit: Arif Biswas - stock.adobe.com
August 19th 2024

Novel Targeted Therapies Show Superiority in Relapsed/Refractory CLL

Nameera Temkar, MD
A meta-analysis demonstrated the superiority of Bruton tyrosine kinase inhibitors (BKTi) in the overall survival of patients with chronic lymphocytic leukemia compared with other therapies.
Quality of life in patients with hemophilia A or B benefits from the use of concizumab | image credit: Patrick Daxenbichler - stock.adobe.com
August 18th 2024

Patient-Reported Outcomes Favor Concizumab Prophylaxis in Hemophilia A or B

Connor Iapoce
Analysis of the phase 3 explorer7 (NCT04083781) study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors.
AML cells | image credit: LASZLO - stock.adobe.com
August 17th 2024

AML Treatment Has Shifted Toward More Personalized Approach

AJMC Contributor
Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease.
Cytokine release concept | image credit: Bijac - stock.adobe.com
August 16th 2024

Cytokine Release Syndrome in CAR T-Cell Therapy: A Common Yet Controllable Complication in DLBCL

Kimberly Rath, PharmD
CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases.
Maria Amaya, MD, PhD
August 16th 2024

Real-World Outcomes Not Always Reflected in Clinical Trials: Dr Maria Amaya

Kyle Munz
Maria Amaya, MD, PhD, University of Colorado School of Medicine, explores discrepancies between real-world data and clinical trial outcomes, as well as her experience ensuring the reliability of real-world analysis.
Patients with PNH may become more active following ravulizumab therapy | image credit: sutadimages - stock.adobe.com
August 16th 2024

Ravulizumab Boosts Activity Levels, Quality of Life in Patients With PNH

Connor Iapoce
Ravulizumab therapy may enable patients with paroxysmal nocturnal hemoglobinuria (PNH) to comparable achieve activity levels and patient-reported outcomes to the US general population.
Guidelines folder | Image Credit: tashatuvango-stock.adobe.com
August 16th 2024

New Guidelines Clarify MDS Classification, Highlight Diagnostic Nuances

Gayle Turim Dickstein
Authors acknowledge that both the 2022 World Health Organization and International Consensus Classification myelodysplastic syndrome criteria sets have value, while sorting out their similarities and differences.
FDA approval | Image Credit: Tada Images - stock.adobe.com
August 15th 2024

FDA Approves Axatilimab-csfr for Chronic Graft-vs-Host Disease

Cameron Santoro
The FDA has approved axatilimab-csfr (Niktimvo) for treating adults and children with chronic graft-versus-host disease who have progressed on at least 2 prior treatments.
Anna Sureda, MD, PhD
August 10th 2024

Advancements in R/R Lymphoma: Bispecific Antibodies in Focus

Brooke McCormick Maggie L. Shaw
In part 1 of our interview with Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation, she summarized the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular lymphoma (FL).
Precision medicine | Image Credit: leowolfert-stock.adobe.com
August 8th 2024

Opportunities Remain for Expanding Precision Medicine in CLL

AJMC Contributor
As the treatment landscape for chronic lymphocytic leukemia (CLL) has moved into an era where targeted treatments are a mainstay of treatment, new opportunities to tailor therapy have emerged.
MM blood test | Image Credit: luchschenF-stock.adobe.com
August 6th 2024

Novel Therapies Needed for Older Patients With RRMM

Maggie L. Shaw
Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.
Sickle cell retinopathy is a manifestation of SCD that occurs in the eye and can cause detriments to patients’ vision| image credit: Катерина Євтехова - stock.adobe.com
August 5th 2024

The Benefits of More Sickle Cell Retinopathy Screening for Patients With SCD

Kyle Munz
A systematic analysis that reviewed screening for sickle cell retinopathy in patients with sickle cell disease (SCD) underscores the importance of advanced imaging measures and further research on screening implementation methods.
doc comforting patient | Image Credit: Seventyfour-stock.adobe.com
August 3rd 2024

Blinatumomab Boosts Survival in MRD-Negative BCP-ALL

Jared Kaltwasser
Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and relapse-free survival.
MDS wooden blocks | Image Credit: Sviatlana - stock.adobe.com
August 2nd 2024

Report: ESAs Largely Ineffective in Lower-Risk MDS

Jared Kaltwasser
Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs).
doc interviewing patient | Image Credit: ChasingMagic/peopleimages.com-stock.adobe.com
August 1st 2024

Accurately Capturing Experiences of Patients With NHL

Jared Kaltwasser
Investigators wanted to know how well the NFlymSI-18 assessment was able to assess patient-reported outcomes in people with indolent B-cell non-Hodgkin lymphoma (NHL).
FDA | Image Credit: ra2studio-stock.adobe.com
July 31st 2024

Daratumumab and Hyaluronidase-fihj–Based Quadruplet Regimen Approved in MM

Maggie L. Shaw
Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant.
awareness of hematologic disorders | Image Credit: Orawan-stock.adobe.com
July 30th 2024

ActivinA Helps B-ALL Cells by Inducing Extracellular Vesicles

Jared Kaltwasser
A new study suggests inhibiting ActivinA might improve the efficacy of chemotherapy in patients with B-cell acute lymphoblastic leukemia (B-ALL).
stem cell transplant | Image Credit: Vadim-stock.adobe.com.jpeg
July 28th 2024

HCT Outcomes Show Improvement With Posttransplant Cyclophosphamide

Karen Jacobson-Sive
Post–hematopoietic cell transplantation (HCT) prophylaxis using cyclophosphamide to stave off graft-vs-host disease had positive results compared with calcineurin inhibitor–based prophylaxis, regardless of whether the patient had a matched or unmatched donor.
<12345678
...
26>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo